RxDoctor Payments Data

Latricia Hickenbottom

Psychiatric/Mental Health · Mobile, ALNPI 1700343811

Payments from drug & device makers

$3,004in general payments, 2019–2025

Across 182 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$737
  • Alkermes, Inc.$485
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$466
  • AbbVie$400
  • Otsuka America Pharmaceutical, Inc.$333
  • Johnson & Johnson$242
  • plus $340 from 4 others

What the payments were for

  • Food & beverage$3,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,004 in reported general payments places this provider in the 70th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$832
Medicare patients
17
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate59$166,785
Austedo XrDeutetrabenazine13$77,878
Abilify MaintenaAripiprazole23$62,862
Lurasidone Hcl36$23,548
RexultiBrexpiprazole14$20,897
Risperidone ErRisperidone Microspheres12$10,984
Aripiprazole62$3,549
Asenapine Maleate21$2,561
Paliperidone ErPaliperidone12$2,065
Fluphenazine Decanoate17$1,676
Divalproex Sodium ErDivalproex Sodium38$1,316
Olanzapine58$1,249
Quetiapine Fumarate77$975
Clozapine13$967
Quetiapine Fumarate ErQuetiapine Fumarate19$886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$242$166,78559 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$333$83,75937 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$737$77,87813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →